At present, many physicians adopt autoSCT as upfront consolidation in patients achieving a CR or partial remission (PR) in the following subtypes: PTCL—not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and ALCL, ALK-negative. This evidence concerns the gene ALK and mature T-cell and NK-cell non-Hodgkin lymphoma.